Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
11
05
2022
accepted:
05
08
2022
pubmed:
27
8
2022
medline:
16
12
2022
entrez:
26
8
2022
Statut:
ppublish
Résumé
Brentuximab vedotin (BV) has been approved for CD30-expressing cutaneous T-cell lymphoma (CTCL) after at least one previous systemic treatment. However, real clinical practice is still limited. To evaluate the response and tolerance of BV in a cohort of patients with CTCL. We analysed CTCL patients treated with BV from the Spanish Primary Cutaneous Lymphoma Registry (RELCP). Sixty-seven patients were included. There were 26 females and the mean age at diagnosis was 59 years. Forty-eight were mycosis fungoides (MF), 7 Sézary syndrome (SS) and 12 CD30+ lymphoproliferative disorders (CD30 LPD). Mean follow-up was 18 months. Thirty patients (45%) showed at least 10% of CD30+ cells among the total lymphocytic infiltrate. The median number of BV infusions received was 7. The overall response rate (ORR) was 67% (63% in MF, 71% in SS and 84% in CD30 LPD). Ten of 14 patients with folliculotropic MF (FMF) achieved complete or partial response (ORR 71%). The median time to response was 2.8 months. During follow-up, 36 cases (54%) experienced cutaneous relapse or progression. The median progression free survival (PFS) was 10.3 months. The most frequent adverse event was peripheral neuropathy (PN) (57%), in most patients (85%), grades 1 or 2. These results confirm the efficacy and safety of BV in patients with advanced-stage MF, and CD30 LPD. In addition, patients with FMF and SS also showed a favourable response. Our data suggest that BV retreatment is effective in a proportion of cases.
Sections du résumé
BACKGROUND
BACKGROUND
Brentuximab vedotin (BV) has been approved for CD30-expressing cutaneous T-cell lymphoma (CTCL) after at least one previous systemic treatment. However, real clinical practice is still limited.
OBJECTIVES
OBJECTIVE
To evaluate the response and tolerance of BV in a cohort of patients with CTCL.
METHODS
METHODS
We analysed CTCL patients treated with BV from the Spanish Primary Cutaneous Lymphoma Registry (RELCP).
RESULTS
RESULTS
Sixty-seven patients were included. There were 26 females and the mean age at diagnosis was 59 years. Forty-eight were mycosis fungoides (MF), 7 Sézary syndrome (SS) and 12 CD30+ lymphoproliferative disorders (CD30 LPD). Mean follow-up was 18 months. Thirty patients (45%) showed at least 10% of CD30+ cells among the total lymphocytic infiltrate. The median number of BV infusions received was 7. The overall response rate (ORR) was 67% (63% in MF, 71% in SS and 84% in CD30 LPD). Ten of 14 patients with folliculotropic MF (FMF) achieved complete or partial response (ORR 71%). The median time to response was 2.8 months. During follow-up, 36 cases (54%) experienced cutaneous relapse or progression. The median progression free survival (PFS) was 10.3 months. The most frequent adverse event was peripheral neuropathy (PN) (57%), in most patients (85%), grades 1 or 2.
CONCLUSIONS
CONCLUSIONS
These results confirm the efficacy and safety of BV in patients with advanced-stage MF, and CD30 LPD. In addition, patients with FMF and SS also showed a favourable response. Our data suggest that BV retreatment is effective in a proportion of cases.
Substances chimiques
Brentuximab Vedotin
7XL5ISS668
Immunoconjugates
0
Ki-1 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
57-64Subventions
Organisme : Kyowa Hakko Kirin
Informations de copyright
© 2022 European Academy of Dermatology and Venereology.
Références
Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomized, phase 3, multicentre trial. Lancet. 2017;390:556-66.
Kim YH, Tavallaee M, Sundram U, Salva KA, Wood GS, Li S, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sezary syndrome with variable CD30 expression level: a multiinstitution collaborative project. J Clin Oncol. 2015;33:3750-8.
Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, Talpur R. Results of a phase II trial of brentuximab vedotin for CD30+ Cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015;33:3759-65.
Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133:1703-14.
Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110:479-84.
Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Se'zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110:1713-22.
Olsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss F, Geskin L. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood. 2022;140:419-37.
Peñate Y, Servitje O, Machan S, Fernández-de-Misa R, Estrach MT, Acebo E, et al. The first year of the AEVD primary cutaneous lymphoma registry. Actas Dermosifiliogr. 2018;109:610-6.
Papadavid E, Kapniari E, Pappa V, Nikolaou V, Iliakis T, Dalamaga M, et al. Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézarysyndrome with variable CD30 positivity. Br J Dermatol. 2021;185:1035-44.
Geller S, Myskowski PL, Kim YH, Moskowitz A, Horwitz S. The optimal regimen of brentuximab vedotin for CD30+ cutaneous lymphoma: are we there yet? Br J Dermatol. 2018;178:571.
Mahévas T, Ram-Wolff C, Battistella M, Pennamen MDV, Rivet J, Brice P, et al. Dramatic response to brentuximab vedotin in refractory nontransformed CD30- mycosis fungoides allowing allogeneic stem cell transplant and long-term complete remission. Br J Dermatol. 2019;180:1517-20.
Zhang C, Chairatchaneeboon M, Haun P, Landsburg D, Kim EJ. Treatment of CD30- negative refractory mycosis fungoides with brentuximab vedotin. JAMA Dermatol. 2018;154:109-10.
Gosmann J, Stadler R. Long term survival, time to next treatment and CD30 expression in patients with advanced CD30+ cutaneous T-cell lymphoma treated with Brentuximab vedotin - A monocentric retrospective analysis of twelve patients. J Dtsch Dermatol Ges. 2022;20:514-7.
Henderson MH, Davison K, Popradi G. Real-world effectiveness of brentuximab vedotin in the treatment of CD30-positive cutaneous T-cell lymphoma: a single-centreretrospective review. Br J Dermatol. 2022;186:379-81.
Lewis DJ, Talpur R, Huen AO, Tetzlaff MT, Duvic M. Brentuximab vedotin for patients with refractory lymphomatoid papulosis: an analysis of phase 2 results. JAMA Dermatol. 2017;153:1302-6.
Lewis DJ, Haun PL, Samimi SS, Vittorio CC, Villasenor-Park J, Barta SK, et al. Brentuximab vedotin for relapsed or refractory sezary syndrome. JAMA Dermatol. 2021;157:317-21.
Domingo-Domenech E, Duarte RF, Boumedil A, Onida F, Gabriel I, Finel H, et al. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sezary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2021;56:1391-401.
André R, Ram-Wolff C, Battistella M, Peffault de Latour R, Petit A, Bouaziz JD, et al. Effectiveness of brentuximab vedotin before and after allogeneic stem-cell transplantation in the management of transformed mycosis fungoides. Br J Dermatol. 2020;182:1503-4.
Engelina S, Saggu M, Yoo J, Shah F, Stevens A, Irwin C, et al. Brentuximab a novel antibody therapy: real-world use confirms efficacy and tolerability for CD30-positive cutaneous lymphoma. Br J Dermatol. 2020;182:788-818.
Kim YH, Prince HM, Whittaker S, Horwitz SM, Duvic M, Bechter O, et al. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: an ALCANZA sub-analysis. Eur J Cancer. 2021;148:411-21.